Advertisement

Topics

To Demonstrate the Relative Bioavailability of Cilostazol 50 mg Tablets Under Fasting Conditions

2014-08-27 03:22:54 | BioPortfolio

Summary

To demonstrate the relative bioavailability of Cilostazol 50 mg tablets under fasting conditions.

Study Design

Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Pain

Intervention

Cilostazol 50 mg Tablets (Eon Pharma, LLC, USA), Pletal (Cilostazol) 50 mg Tablets (Otsuka Pharma Co, Ltd., USA)

Status

Completed

Source

Sandoz Inc.

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:22:54-0400

Clinical Trials [1712 Associated Clinical Trials listed on BioPortfolio]

Fasted Bioavailability Study of Cilostazol Tablets, 100 mg

The purpose of this study is to evaluate and compare the relative bioavailability of a test formulation of cilostazol tablets to an equivalent dose of Pletal® (cilostazol) tablets after a...

Fasted Bioavailability Study of Cilostazol Tablets, 50mg

The purpose of this study is to evaluate and compare the relative bioavailability of a test formulation of cilostazol tablets to an equivalent dose of Pletal® (cilostazol) tablets after a...

Cilostazol 50 mg Tablets Under Fasting Conditions

This study will compare the relative bioavailability (rate and extent of absorption) of 50 mg Cilostazol Tablets manufactured by TEVA Pharmaceuticals Industries Ltd. and distributed by TEV...

Bioequivalency Study of 50 mg Cilostazol Tablets Under Fasting Conditions

The objective of this study was the bioequivalence of a Roxane Laboratories' Cilostazol Tablets, 50 mg, to PLETAL® Tablets, 50 mg (OTSUKA Pharmaceuticals) under fasting conditions using a...

Cilostazol 100 mg Tablet Formulations Under Fasting Conditions

The objective of this randomized, single-dose, two-way evaluation is to compare the bioequivalence of a test cilostazol formulation to an equivalent oral dose of the commercially available...

PubMed Articles [252 Associated PubMed Articles listed on BioPortfolio]

Pre-treatment with sumatriptan for cilostazol induced headache in healthy volunteers.

Previous studies indicate that sumatriptan is not effective when second messenger levels are high as after cilostazol provocation. Therefore, we have conducted the present study, where sumatriptan is ...

Cilostazol for treatment of cerebral infarction.

Stroke not only causes critical disability and death but is also a cause of anxiety with the possibility of secondary cardiovascular events including secondary ischemic stroke. Indeed, patients with a...

Association of platelet response to cilostazol with clinical outcome and CYP genotype in patients with cerebral infarction.

Cilostazol, an anti-platelet drug that inhibits phosphodiesterase 3, is beneficial for patients with atherothrombosis. In contrast to other anti-platelet drugs such as aspirin and thienopyridines, lit...

MicroRNA-132 targeting PTEN contributes to cilostazol-promoted vascular smooth muscle cell differentiation.

Cilostazol, beyond its antiplatelet effect, is also capable of promoting vascular smooth muscle cell (VSMC) differentiation. The aim of this study was to explore the potential role of PTEN, known to a...

Anti-inflammatory properties of cilostazol: Its interruption of DNA binding activity of NF-κB from the Toll-like receptor signaling pathways.

Cilostazol, a selective inhibitor of phosphodiesterase type III with anti-platelet, anti-mitogenic, and vasodilating properties, is widely used to treat ischemic symptoms of peripheral vascular diseas...

Medical and Biotech [MESH] Definitions

Tablets coated with material that delays release of the medication until after they leave the stomach. (Dorland, 28th ed)

A disaccharide of GLUCOSE and GALACTOSE in human and cow milk. It is used in pharmacy for tablets, in medicine as a nutrient, and in industry.

A method of treating an ALLERGY by administering ALLERGENS, in liquid formulation or tablets, to the ORAL MUCOSA under the tongue.

Solid dosage forms, of varying weight, size, and shape, which may be molded or compressed, and which contain a medicinal substance in pure or diluted form. (Dorland, 28th ed)

Usually inert substances added to a prescription in order to provide suitable consistency to the dosage form. These include binders, matrix, base or diluent in pills, tablets, creams, salves, etc.

More From BioPortfolio on "To Demonstrate the Relative Bioavailability of Cilostazol 50 mg Tablets Under Fasting Conditions"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pain
Pain is defined by the International Association for the Study of Pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage”. Some illnesses can be excruci...


Searches Linking to this Trial